We are live on
!
Find out more
FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$237M
1-Year Est. Return
107.53%
This Fund
S&P 500
This Quarter
Est. Return
+4.25%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$354M
AUM Growth
+$75.5M
(+27%)
Cap. Flow
+$95.9M
Cap. Flow
% of AUM
27.09%
Top 10 Holdings %
Top 10 Hldgs %
78.19%
Holding
22
New
6
Increased
6
Reduced
7
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
+$65.3M |
| 2 |
AERI
Aerie Pharmaceuticals
AERI
|
+$15M |
| 3 |
Voyager Therapeutics
VYGR
|
+$8.21M |
| 4 |
MDCO
Medicines Co
MDCO
|
+$8.15M |
| 5 |
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
|
+$6.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMMU
Immunomedics Inc
IMMU
|
+$11.7M |
| 2 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$6.21M |
| 3 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$5.01M |
| 4 |
Alector
ALEC
|
+$1.22M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
+$679K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TPTX
1
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $74.5M | 21.06% |
+1,830,265
| New | +$65.3M |
|
2
Insmed
INSM
$23.3B
| $40M | 11.3% |
1,561,185
+27,302
| +2% | +$761K |
|
3
Ascendis Pharma A/S
ASND
$16.7B
| $28.3M | 7.99% |
245,424
| – | – |
|
|
4
Alector
ALEC
$167M
| $21.7M | 6.14% |
1,143,462
-60,000
| -5% | -$1.22M |
|
5
Cytokinetics
CYTK
$11B
| $21.4M | 6.04% |
1,898,970
+175,800
| +10% | +$1.7M |
|
|
BHVN
6
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $18.8M | 5.32% |
429,690
-88,870
| -17% | -$5.01M |
|
|
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
| $18.4M | 5.2% |
2,571,258
-60,000
| -2% | -$679K |
|
8
Replimune Group
REPL
$843M
| $18M | 5.09% |
1,228,656
-1,000
| -0.1% | -$14.5K |
|
|
OPTN
9
DELISTED
OptiNose
OPTN
| $17.9M | 5.05% |
168,146
+6,319
| +4% | +$832K |
|
|
AERI
10
DELISTED
Aerie Pharmaceuticals
AERI
| $17.7M | 5.01% |
600,000
+388,177
| +183% | +$15M |
|
|
11
Voyager Therapeutics
VYGR
$189M
| $14.6M | 4.13% |
536,771
+358,967
| +202% | +$8.21M |
|
|
MYOK
12
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $12.9M | 3.65% |
257,452
-127,541
| -33% | -$6.21M |
|
13
Rhythm Pharmaceuticals
RYTM
$7.06B
| $10.3M | 2.92% |
469,482
+64,456
| +16% | +$1.63M |
|
|
MDCO
14
DELISTED
Medicines Co
MDCO
| $9.11M | 2.57% |
+249,672
| New | +$8.15M |
|
|
NGM
15
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $6.9M | 1.95% |
+471,269
| New | +$6.9M |
|
16
Veracyte
VCYT
$4.54B
| $5.7M | 1.61% |
+200,000
| New | +$5M |
|
|
IMMU
17
DELISTED
Immunomedics Inc
IMMU
| $5.35M | 1.51% |
385,751
-776,214
| -67% | -$11.7M |
|
18
SI-BONE Inc
SIBN
$736M
| $4.18M | 1.18% |
205,621
| – | – |
|
|
AERI
19
CALL
DELISTED
Aerie Pharmaceuticals
AERI
| $2.97M | 0.84% |
+100,500
| New | +$3.87M |
|
|
AERI
20
PUT
DELISTED
Aerie Pharmaceuticals
AERI
| $2.97M | 0.84% |
+100,500
| New | +$3.87M |
|
21
Arbutus Biopharma
ABUS
$871M
| $1.26M | 0.36% |
608,151
-196,295
| -24% | -$502K |
|
22
Kiniksa Pharmaceuticals
KNSA
$4.83B
| $866K | 0.24% |
63,922
| – | – |
|
Similar funds
BCM
ICMM
AG
FL
TS
EA
PVM
MFA
Foresite Capital Management IV's Q2 2019 Portfolio in Review
As of Q2 2019, Foresite Capital Management IV held 22 positions worth $354M, up 27% from $278M the previous quarter. Its ten largest holdings account for 78% of the portfolio.
Foresite Capital Management IV deployed $95.9M of net new capital in Q2 2019, opening 6 new positions and adding to 6 existing holdings. Its largest new stake was Turning Point Therapeutics, Inc. Common Stock: 1,830,265 shares worth $74.5M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 88% a quarter earlier.
On the sell side, the largest reduction was Immunomedics Inc, an estimated $11.7M trimmed.
- Foresite Capital Management IV's largest Q2 2019 buy was Turning Point Therapeutics, Inc. Common Stock: 1,830,265 shares worth $74.5M.
- Foresite Capital Management IV added most to Aerie Pharmaceuticals in Q2 2019, an estimated $15M increase.
- Foresite Capital Management IV's biggest Q2 2019 reduction was Immunomedics Inc, cutting an estimated $11.7M.
- Foresite Capital Management IV's ten largest holdings make up 78% of its $354M portfolio in Q2 2019.
- Foresite Capital Management IV opened 6 new positions and closed 0 in Q2 2019.
- Foresite Capital Management IV's portfolio value rose 27% quarter-over-quarter to $354M.
Based on Foresite Capital Management IV's 13F filing for Q2 2019, filed 13 Aug 2019.